Potent Rho-kinase (ROCK) inhibitor (IC50
value of approximately 5.6 nM at recombinant human ROCK1 and 2). Decreases pulmonary and systemic arterial blood pressures and increases cardiac output. Exhibits vasodilator activity that is more potent than Y-27632
(Cat.No 1254) or Fasudil
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from GlaxoSmithKline
Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.
Doe et al.